Rhythm is developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.
Developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.
Learn More >
Our lead peptide product candidate, setmelanotide, is a potent, first-in-class MC4R agonist for the treatment of rare genetic disorders of obesity.
LEARN ABOUT OUR PRODUCT PIPELINE >
The Genetic Obesity Project website sponsored by Rhythm is dedicated to improving the understanding of severe obesity that is caused by specific genetic defects.
VISIT WEBSITE >
October 31, 2017
Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
October 10, 2017
Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
VIEW ALL NEWS >